{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:43:00Z","timestamp":1780393380094,"version":"3.54.1"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,9,27]],"date-time":"2020-09-27T00:00:00Z","timestamp":1601164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Investigator Initiated Research","award":["WS872934"],"award-info":[{"award-number":["WS872934"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>About half of RA patients treated with TNF\u03b1 inhibitors either do not respond or lose their initial therapeutic response over time. The clinical response is measured by reduction in DAS28, which primarily reflects inflammation. However, other effects of TNF\u03b1 inhibitors, such as impact on bone erosion, are not assessed by DAS28. We aimed to examine the effect of TNF\u03b1 inhibitors on bone density, bone biomarkers and cytokine production in responder and non-responder patients and assessed mechanisms of action.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>BMD in the lumbar spine and femur neck of 117 RA patients was measured by DEXA scan. Bone turnover biomarkers CTX, osteoprotegerin (OPG), osteocalcin and RANKL were measured by ELISA. Levels of 16 cytokines in plasma and in tissue culture supernatants of ex vivo T cells were measured by multiplex assays and ELISA. The effect of treatment with TNF\u03b1 inhibitors on blood mononuclear cell (MNC) differentiation to osteoclast precursors (OCP) was measured flow cytometry and microscopy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>TNF\u03b1 inhibitors improved lumbar spine BMD but had modest effects on blood bone biomarkers, irrespective of patients\u2019 clinical response. Blood OCP numbers and the ability of monocytes to differentiate to OCP in vitro declined after treatment. Treatment also reduced RANK expression and IL-20 production. BMD improvement correlated with reduced levels of IL-20 in responder patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This study reveals that TNF\u03b1 inhibitors reduce lumbar spine bone loss in RA patients irrespective of changes in DAS28. The reduction in bone loss is associated with reduction in IL-20 levels in responder patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa551","type":"journal-article","created":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T19:28:23Z","timestamp":1596655703000},"page":"947-957","source":"Crossref","is-referenced-by-count":9,"title":["TNF\u03b1 inhibitors reduce bone loss in rheumatoid arthritis independent of clinical response by reducing osteoclast precursors and IL-20"],"prefix":"10.1093","volume":"60","author":[{"given":"Mohammed","family":"Al-Bogami","sequence":"first","affiliation":[{"name":"Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Bystrom","sequence":"additional","affiliation":[{"name":"Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Clanchy","sequence":"additional","affiliation":[{"name":"Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taher E","family":"Taher","sequence":"additional","affiliation":[{"name":"Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Mangat","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Royal Free Hospital, NHS Foundation Trust London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard O","family":"Williams","sequence":"additional","affiliation":[{"name":"Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali S","family":"Jawad","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Barts Health NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1561-784X","authenticated-orcid":false,"given":"Rizgar A","family":"Mageed","sequence":"additional","affiliation":[{"name":"Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,27]]},"reference":[{"key":"2021020119054049600_keaa551-B1","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1056\/NEJMra1004965","article-title":"The pathogenesis of rheumatoid arthritis","volume":"365","author":"McInnes","year":"2011","journal-title":"N Engl J Med"},{"key":"2021020119054049600_keaa551-B2","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","article-title":"Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis","volume":"41","author":"Maini","year":"1998","journal-title":"Arthritis Rheum"},{"key":"2021020119054049600_keaa551-B3","doi-asserted-by":"crossref","first-page":"R154","DOI":"10.1186\/ar3107","article-title":"Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis","volume":"12","author":"Kim","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"2021020119054049600_keaa551-B4","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.0105-2896.2005.00324.x","article-title":"The role of T lymphocytes in bone metabolism","volume":"208","author":"Weitzmann","year":"2005","journal-title":"Immunol Rev"},{"key":"2021020119054049600_keaa551-B5","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1172\/JCI11176","article-title":"TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand","volume":"106","author":"Lam","year":"2000","journal-title":"J Clin Invest"},{"key":"2021020119054049600_keaa551-B6","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/art.10097","article-title":"Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin","volume":"46","author":"Redlich","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2021020119054049600_keaa551-B7","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1002\/art.21021","article-title":"Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models","volume":"52","author":"Schett","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2021020119054049600_keaa551-B8","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nrrheum.2011.133","article-title":"Rheumatoid arthritis: repair of erosion in RA\u2013shifting the balance to formation","volume":"7","author":"Gravallese","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"2021020119054049600_keaa551-B9","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1136\/ard.2007.070839","article-title":"Bone mineral density in patients with recently diagnosed, active rheumatoid arthritis","volume":"66","author":"Guler-Yuksel","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2021020119054049600_keaa551-B10","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.20217","article-title":"Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial","volume":"50","author":"Keystone","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2021020119054049600_keaa551-B11","doi-asserted-by":"crossref","first-page":"R61","DOI":"10.1186\/ar2219","article-title":"A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab","volume":"9","author":"Marotte","year":"2007","journal-title":"Arthritis Res Ther"},{"key":"2021020119054049600_keaa551-B12","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1136\/ard.2005.044198","article-title":"Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis","volume":"65","author":"Vis","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"2021020119054049600_keaa551-B13","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1172\/JCI0215582","article-title":"Osteoclasts are essential for TNF-alpha-mediated joint destruction","volume":"110","author":"Redlich","year":"2002","journal-title":"J Clin Invest"},{"key":"2021020119054049600_keaa551-B14","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/art.10388","article-title":"High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment","volume":"46","author":"Ziolkowska","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2021020119054049600_keaa551-B15","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/art.23417","article-title":"Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial","volume":"58","author":"Cohen","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2021020119054049600_keaa551-B16","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1136\/annrheumdis-2011-201024","article-title":"Incomplete response of inflammatory arthritis to TNFalpha blockade is associated with the Th17 pathway","volume":"71","author":"Alzabin","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2021020119054049600_keaa551-B17","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1186\/ar4179","article-title":"IL-17-mediated Bcl-2 expression regulates survival of fibroblast-like synoviocytes in rheumatoid arthritis through STAT3 activation","volume":"15","author":"Lee","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"2021020119054049600_keaa551-B18","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1084\/jem.20061775","article-title":"Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction","volume":"203","author":"Sato","year":"2006","journal-title":"J Exp Med"},{"key":"2021020119054049600_keaa551-B19","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI5703","article-title":"IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis","volume":"103","author":"Kotake","year":"1999","journal-title":"J Clin Invest"},{"key":"2021020119054049600_keaa551-B20","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3389\/fimmu.2015.00151","article-title":"Differential Effects of IL-17A and TNF-alpha on osteoblastic differentiation of isolated synoviocytes and on bone explants from arthritis patients","volume":"6","author":"Osta","year":"2015","journal-title":"Front Immunol"},{"key":"2021020119054049600_keaa551-B21","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1084\/jem.20072707","article-title":"Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells","volume":"205","author":"Notley","year":"2008","journal-title":"J Exp Med"},{"key":"2021020119054049600_keaa551-B22","first-page":"S93","article-title":"The Disease Activity Score and the EULAR response criteria","volume":"23","author":"Fransen","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2021020119054049600_keaa551-B23","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s12016-017-8610-y","article-title":"Response to treatment with TNF alpha inhibitors in rheumatoid arthritis is associated with high levels of GM-CSF and GM-CSF(+) T lymphocytes","volume":"53","author":"Bystrom","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"2021020119054049600_keaa551-B24","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1172\/JCI200316069","article-title":"Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis","volume":"111","author":"Ritchlin","year":"2003","journal-title":"J Clin Invest"},{"key":"2021020119054049600_keaa551-B25","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/jbmr.3966","article-title":"Ovariectomy activates chronic low-grade inflammation mediated by memory T cells, which promotes osteoporosis in mice","volume":"35","author":"Cline-Smith","year":"2020","journal-title":"J Bone Miner Res"},{"key":"2021020119054049600_keaa551-B26","doi-asserted-by":"crossref","first-page":"5692","DOI":"10.1038\/s41598-020-62562-2","article-title":"Interleukin 17A: a Janus-faced regulator of. osteoporosi","volume":"10","author":"Scheffler","year":"2020","journal-title":"s. Sci Rep"},{"key":"2021020119054049600_keaa551-B27","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.0105-2896.2005.00331.x","article-title":"AlphaVbeta3 and macrophage colony-stimulating factor: partners in osteoclast biology","volume":"208","author":"Ross","year":"2005","journal-title":"Immunol Rev"},{"key":"2021020119054049600_keaa551-B28","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/ard.2007.076604","article-title":"Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis","volume":"67","author":"Chopin","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2021020119054049600_keaa551-B29","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1136\/ard.2009.127787","article-title":"Stable bone mineral density in lumbar spine and hip in contrast to bone loss in the hands during long-term treatment with infliximab in patients with rheumatoid arthritis","volume":"70","author":"Eekman","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2021020119054049600_keaa551-B30","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1136\/annrheumdis-2011-201075","article-title":"Interleukin-6 receptor blockade induces limited repair of bone erosions in rheumatoid arthritis: a micro CT study","volume":"72","author":"Finzel","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2021020119054049600_keaa551-B31","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.4049\/jimmunol.1600138","article-title":"IL-17 promotes neutrophil-mediated immunity by activating microvascular pericytes and not endothelium","volume":"197","author":"Liu","year":"2016","journal-title":"J Immunol"},{"key":"2021020119054049600_keaa551-B32","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/jcb.22326","article-title":"IL-17 induces osteoclastogenesis from human monocytes alone in the absence of osteoblasts, which is potently inhibited by anti-TNF-alpha antibody: a novel mechanism of osteoclastogenesis by IL-17","volume":"108","author":"Yago","year":"2009","journal-title":"J Cell Biochem"},{"key":"2021020119054049600_keaa551-B33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/art.38896","article-title":"Combined inhibition of tumor necrosis factor alpha and interleukin-17 as a therapeutic opportunity in rheumatoid arthritis: development and characterization of a novel bispecific antibody","volume":"67","author":"Fischer","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2021020119054049600_keaa551-B34","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1136\/ard.2008.091611","article-title":"Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss","volume":"68","author":"Wijbrandts","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2021020119054049600_keaa551-B35","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1136\/ard.2003.017780","article-title":"Bone mineral density in patients with rheumatoid arthritis treated with infliximab","volume":"64","author":"Vis","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2021020119054049600_keaa551-B36","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1002\/jbmr.2228","article-title":"Enhanced immunoprotective effects by anti-IL-17 antibody translates to improved skeletal parameters under estrogen deficiency compared with anti-RANKL and anti-TNF-alpha antibodies","volume":"29","author":"Tyagi","year":"2014","journal-title":"J Bone Miner Res"},{"key":"2021020119054049600_keaa551-B37","first-page":"1167","article-title":"The Role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies. Ann Rheum","volume":"78","author":"McGonagle","year":"2019","journal-title":"Dis"},{"key":"2021020119054049600_keaa551-B38","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/art.40447","article-title":"Augmented Th17 differentiation leads to cutaneous and Synovio-Entheseal inflammation in a novel model of psoriatic arthritis","volume":"70","author":"Yang","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2021020119054049600_keaa551-B39","doi-asserted-by":"crossref","first-page":"10928","DOI":"10.1038\/ncomms10928","article-title":"IL-17-producing \u03b3\u03b4 T cells enhance bone regeneration","volume":"7","author":"Ono","year":"2016","journal-title":"Nat Commun"},{"key":"2021020119054049600_keaa551-B40","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/cei.12449","article-title":"Distribution of interleukin-10 family cytokines in serum and synovial fluid of patients with inflammatory arthritis reveals different contribution to systemic and joint inflammation","volume":"179","author":"Scrivo","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"2021020119054049600_keaa551-B41","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1002\/art.33446","article-title":"Interleukin-22 promotes osteoclastogenesis in rheumatoid arthritis through induction of RANKL in human synovial fibroblasts","volume":"64","author":"Kim","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2021020119054049600_keaa551-B42","doi-asserted-by":"crossref","first-page":"24339","DOI":"10.1038\/srep24339","article-title":"Anti-IL-20 monoclonal antibody promotes bone fracture healing through regulating IL-20-mediated osteoblastogenesis","volume":"6","author":"Hsu","year":"2016","journal-title":"Sci Rep"},{"key":"2021020119054049600_keaa551-B43","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.3899\/jrheum.111027","article-title":"Increased serum interleukin 22 in patients with rheumatoid arthritis and correlation with disease activity","volume":"39","author":"da Rocha","year":"2012","journal-title":"J Rheumatol"},{"key":"2021020119054049600_keaa551-B44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/2690402","article-title":"Effect of tumor necrosis factor inhibitor therapy on osteoclasts precursors in rheumatoid arthritis","volume":"2017","author":"Perp\u00e9tuo","year":"2017","journal-title":"Biomed Res Int"},{"key":"2021020119054049600_keaa551-B45","doi-asserted-by":"crossref","first-page":"R152","DOI":"10.1186\/ar2046","article-title":"Identification of a human peripheral blood monocyte subset that differentiates into osteoclasts","volume":"8","author":"Komano","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"2021020119054049600_keaa551-B46","doi-asserted-by":"crossref","first-page":"R14","DOI":"10.1186\/ar2915","article-title":"CD16 (FcRgammaIII) as a potential marker of osteoclast precursors in psoriatic arthritis","volume":"12","author":"Chiu","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"2021020119054049600_keaa551-B47","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.0105-2896.2005.00338.x","article-title":"Rheumatic diseases: the effects of inflammation on bone","volume":"208","author":"Walsh","year":"2005","journal-title":"Immunol Rev"},{"key":"2021020119054049600_keaa551-B48","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1084\/jem.20111566","article-title":"TNF-induced osteoclastogenesis and inflammatory bone resorption are inhibited by transcription factor RBP-J","volume":"209","author":"Zhao","year":"2012","journal-title":"J Exp Med"},{"key":"2021020119054049600_keaa551-B49","doi-asserted-by":"crossref","first-page":"4977","DOI":"10.4049\/jimmunol.1502044","article-title":"RBP-J-regulated miR-182 promotes TNF-\u03b1-induced osteoclastogenesis","volume":"196","author":"Miller","year":"2016","journal-title":"J Immunol"},{"key":"2021020119054049600_keaa551-B50","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s13075-016-1197-5","article-title":"Increase in circulating Th17 cells during anti-TNF therapy is associated with ultrasonographic improvement of synovitis in rheumatoid arthritis","volume":"18","author":"Hull","year":"2016","journal-title":"Arthritis Res Ther"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/2\/947\/36167895\/keaa551.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/2\/947\/36167895\/keaa551.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T03:27:09Z","timestamp":1612322829000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/2\/947\/5912187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,27]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,9,27]]},"published-print":{"date-parts":[[2021,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa551","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,2,1]]},"published":{"date-parts":[[2020,9,27]]}}}